Targeting ALK - From Discovery to Frontline Treatment

(45:52)

What targeted therapies are used for people with the ALK mutation?

(1:5)

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw

(42:31)

Targeting ALK rearrangements in non-small cell lung cancer

(1:1econd)

TARGETING ALK POSITIVE LUNG CANCER: BRUCE’S STORY

(1:33)

Alecensa: Targeted Therapy for ALK-Positive Lung Cancer

(4:23)

Targeting ALK - Discovery to Frontline Treatment

(45:52)

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

(4:5)

January 10, 2025

(36)

Targeting EGFR and ALK mutations

(2:51)

Introduction to ALK inhibitors

(6:17)

The Evolution of ALK/ROS1-Targeted TKIs

(3:31)

A Case of ALK-Rearranged Non–Small Cell Lung Cancer

(3:26)

Sequencing Strategies for ALK-Targeted Therapy

(6:36)

Management of Adverse Events for ALK-Targeted TKIs

(4:4)

New FDA-Approved Targeted Therapy For ALK Positive Lung Cancers (NSCLC) – Excellent Remission Rates!

(19:34)

Enigma (Elucidating Novel Immune and Genomic Markers for ALK) with Drs. Gainor and Lin.

(58:12)

Targeted TKIs Used for Treatment of ALK-Positive NSCLC

(6:22)

How do ALK-inhibitors work in ALK-positive lung cancer?

(2:50)